The Novo Nordisk headquarters in Bagsvaerd, Denmark. Photo: Bloomberg
Stine Jacobsen and Maggie Fick
Reuters
Novo Nordisk has appointed Poul Weihrauch, CEO of US food giant Mars, as board observer as the Danish drugmaker seeks to strengthen its position in the highly competitive US obesity market.
The maker of weight-loss drug Wegovy announced the appointment at its annual general meeting, where shareholders also elected pharmaceutical veterans Jan van de Winkel and Ramona Sequeira to the board, along with Helena Saxon, a board member at fashion retailer H&M.
The Archynetys Health Desk covers public health, medical research, healthcare systems, wellness trends, and science-backed developments that affect readers globally. This desk applies added care to sourcing, evidence, nuance, and plain-language explanation, especially on high-impact health topics.
